{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:52:05Z","timestamp":1794300725462,"version":"4.9.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jbspin.2024.105826","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T11:24:09Z","timestamp":1732965849000},"page":"105826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Optimizing gout treatment: A comprehensive review of current and emerging uricosurics"],"prefix":"10.1016","volume":"92","author":[{"given":"Dan","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2024.105826_bib0560","doi-asserted-by":"crossref","first-page":"e239501","DOI":"10.1001\/jamanetworkopen.2023.9501","article-title":"Trends in Prevalence of Gout Among US Asian Adults, 2011-2018","volume":"6","author":"Yokose","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jbspin.2024.105826_bib0565","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rdc.2014.07.002","article-title":"Gout: a review of nonmodifiable and modifiable risk factors","volume":"40","author":"MacFarlane","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2024.105826_bib0570","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0575","doi-asserted-by":"crossref","first-page":"925219","DOI":"10.3389\/fphar.2022.925219","article-title":"Review of Urate-Lowering Therapeutics: From the Past to the Future","volume":"13","author":"Jenkins","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0580","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/BOR.0b013e3283257b96","article-title":"The role of hyperuricemia in vascular disorders","volume":"21","author":"Edwards","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0585","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/ar2761","article-title":"Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?","volume":"11","author":"Gaffo","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2024.105826_bib0590","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2024.105826_bib0595","first-page":"e64654","article-title":"Allopurinol: Clinical Considerations in the Development and Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Other Associated Drug Reactions","volume":"16","author":"Dillman","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jbspin.2024.105826_bib0600","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2024.105826_bib0605","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s11606-020-05942-8","article-title":"Gout Treatment in the USA from 2009 to 2016: A Repeated Cross-sectional Analysis","volume":"36","author":"Chock","year":"2021","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jbspin.2024.105826_bib0610","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41584-023-01006-3","article-title":"Mechanisms and rationale for uricase use in patients with gout","volume":"19","author":"Schlesinger","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0615","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/molbev\/msw116","article-title":"Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout","volume":"33","author":"Tan","year":"2016","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0620","doi-asserted-by":"crossref","first-page":"667753","DOI":"10.3389\/fphar.2021.667753","article-title":"Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia","volume":"12","author":"Sun","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0625","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib0630","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10067-022-06356-z","article-title":"Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis","volume":"42","author":"Li","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2024.2331101","article-title":"Virtual screening and biological evaluation of natural products as urate transporter 1 (URAT1) inhibitors","author":"Du","year":"2024","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jbspin.2024.105826_bib0640","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23020252","article-title":"Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor","volume":"23","author":"Cai","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.jbspin.2024.105826_bib0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","article-title":"The history and future of probenecid","volume":"12","author":"Robbins","year":"2012","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0650","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40001-022-00982-8","article-title":"Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial","volume":"28","author":"Yang","year":"2023","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jbspin.2024.105826_bib0655","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects","volume":"47","author":"Stocker","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbspin.2024.105826_bib0660","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3899\/jrheum.121301","article-title":"Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population","volume":"40","author":"Pui","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0665","doi-asserted-by":"crossref","first-page":"33082","DOI":"10.1038\/srep33082","article-title":"Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jbspin.2024.105826_bib0670","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jbspin.2024.105826_bib0675","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11926-019-0843-8","article-title":"Cardiovascular Safety of Urate Lowering Therapies","volume":"21","author":"Kang","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2024.105826_bib0680","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00246-020-02427-7","article-title":"Probenecid Improves Cardiac Function in Subjects with a Fontan Circulation and Augments Cardiomyocyte Calcium Homeostasis","volume":"41","author":"Rubinstein","year":"2020","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0685","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout","volume":"71","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0690","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d?","volume":"22","author":"Jansen","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0695","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.jbspin.2024.105826_bib0700","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hep.20634","article-title":"Mechanisms of benzarone and benzbromarone-induced hepatic toxicity","volume":"41","author":"Kaufmann","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jbspin.2024.105826_bib0705","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tox.2014.08.002","article-title":"Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure","volume":"324","author":"Felser","year":"2014","journal-title":"Toxicology"},{"key":"10.1016\/j.jbspin.2024.105826_bib0710","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1021\/acsmedchemlett.0c00176","article-title":"Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity","volume":"11","author":"Uda","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jbspin.2024.105826_bib0715","doi-asserted-by":"crossref","first-page":"7635274","DOI":"10.1155\/2018\/7635274","article-title":"Benzbromarone Attenuates Oxidative Stress in Angiotensin II- and Salt-Induced Hypertensive Model Rats","volume":"2018","author":"Muraya","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jbspin.2024.105826_bib0720","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10067-021-05930-1","article-title":"A historical journey of searching for uricosuric drugs","volume":"41","author":"Jansen","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0725","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1124\/dmd.106.010678","article-title":"Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles","volume":"34","author":"Kumar","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jbspin.2024.105826_bib0730","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/futurepharmacol2020011","article-title":"Pharmacogenetic Perspective for Optimal Gout Management","volume":"2","author":"Alrajeh","year":"2022","journal-title":"Future Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0735","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s10067-024-06933-4","article-title":"Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis","volume":"43","author":"Wu","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0740","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/hr.2016.139","article-title":"Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia","volume":"40","author":"Ohta","year":"2017","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jbspin.2024.105826_bib0745","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib0750","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600mg\/day versus benzbromarone 100-200mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib0755","doi-asserted-by":"crossref","first-page":"263720","DOI":"10.1155\/2014\/263720","article-title":"Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients","volume":"2014","author":"Azevedo","year":"2014","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0760","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib0765","first-page":"CD010457","article-title":"Uricosuric medications for chronic gout","volume":"2014","author":"Kydd","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2024.105826_bib0770","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejim.2023.04.025","article-title":"Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia","volume":"113","author":"Lai","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jbspin.2024.105826_bib0775","doi-asserted-by":"crossref","first-page":"731370","DOI":"10.3389\/fphar.2021.731370","article-title":"A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia","volume":"12","author":"Lai","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0780","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2017.02.013","article-title":"Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study","volume":"233","author":"Lin","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0785","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221116409","article-title":"Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout","volume":"14","author":"Eun","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib0790","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1093\/eurheartj\/ehab619","article-title":"Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout","volume":"42","author":"Kang","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jbspin.2024.105826_bib0795","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","article-title":"Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study","volume":"3","author":"Ogino","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jbspin.2024.105826_bib0800","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21111543","article-title":"Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor","volume":"21","author":"Tian","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.jbspin.2024.105826_bib0805","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.119.259341","article-title":"Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor","volume":"371","author":"Taniguchi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jbspin.2024.105826_bib0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10157-019-01811-9","article-title":"Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia","volume":"24","author":"Kuriyama","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0815","first-page":"59","article-title":"Novel inhibitory effects of dotinurad, a selective urate reabsorption inhibitor, on urate crystal-induced activation of NLRP3 inflammasomes in macrophages","volume":"3","author":"Fikri","year":"2019","journal-title":"Vascular Failure"},{"key":"10.1016\/j.jbspin.2024.105826_bib0820","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10157-019-01816-4","article-title":"Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment","volume":"24","author":"Kumagai","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0825","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10157-019-01818-2","article-title":"Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0830","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10157-019-01802-w","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0835","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10157-020-01849-0","article-title":"Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0840","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10157-020-01851-6","article-title":"A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0845","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5414\/CP204097","article-title":"Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials","volume":"60","author":"Lee","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2024.105826_bib0850","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s10157-019-01817-3","article-title":"The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor","volume":"24","author":"Okui","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0855","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10157-021-02115-7","article-title":"Comparative study of a novel selective urate reabsorption inhibitor \u201cdotinurad\u201d among patient groups with different stages of renal dysfunction","volume":"25","author":"Takahashi","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0860","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.2147\/DDDT.S416025","article-title":"The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis","volume":"17","author":"Yanai","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jbspin.2024.105826_bib0865","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12882-024-03535-9","article-title":"Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease","volume":"25","author":"Amano","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0870","doi-asserted-by":"crossref","first-page":"152279","DOI":"10.1016\/j.semarthrit.2023.152279","article-title":"Systematic review and model-based analysis to identify whether renal safety risks of URAT1 inhibitors are fully determined by uric acid-lowering efficacies","volume":"63","author":"Qu","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105826_bib0875","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1272\/jnms.JNMS.2024_91-403","article-title":"Effect of Dotinurad on Serum Uric Acid Concentration in Chronic Kidney Disease Patients Treated with Febuxostat","volume":"91","author":"Yamada","year":"2024","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.jbspin.2024.105826_bib0880","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4140\/TCP.n.2023.359","article-title":"Hyperuricemia and Gout: The Role of Losartan","volume":"38","author":"Saad","year":"2023","journal-title":"Sr Care Pharm"},{"key":"10.1016\/j.jbspin.2024.105826_bib0885","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/2040622315596119","article-title":"The effect of angiotensin II receptor blockers on hyperuricemia","volume":"6","author":"Wolff","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib0890","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.jhh.1001941","article-title":"Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population","volume":"20","author":"Dang","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jbspin.2024.105826_bib0895","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1475-2840-12-159","article-title":"Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study","volume":"12","author":"Nishida","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0900","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11926-015-0495-2","article-title":"Hyperuricemia, gout, and cardiovascular disease: an update","volume":"17","author":"Abeles","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2024.105826_bib0905","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.mayocp.2022.02.027","article-title":"Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications","volume":"97","author":"Leung","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jbspin.2024.105826_bib0910","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/met.2019.0099","article-title":"Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study)","volume":"18","author":"Buscemi","year":"2020","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.jbspin.2024.105826_bib0915","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/ndt\/gfg341","article-title":"Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients","volume":"18","author":"Chanard","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2024.105826_bib0920","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00558151","article-title":"Antihypertensive and hypouricaemic effects of nitrendipine in chronic renal failure","volume":"36","author":"Weidmann","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0925","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI103905","article-title":"Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man","volume":"38","author":"Yu","year":"1959","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jbspin.2024.105826_bib0930","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/030006057900700605","article-title":"Piroxicam in the treatment of acute gout: a multicentre open study in general practice","volume":"7","author":"Murphy","year":"1979","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jbspin.2024.105826_bib0935","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02041396","article-title":"Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid","volume":"2","author":"Tiitinen","year":"1983","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0940","doi-asserted-by":"crossref","DOI":"10.2174\/0113862073285626240604093210","article-title":"Study on the Mechanism of the Combination of Methotrexate and Leflunomide in the Treatment of Rheumatoid Arthritis Based on Network Pharmacology, Molecular Docking, and in vitro Experimental Verification","author":"Shi","year":"2024","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.jbspin.2024.105826_bib0945","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/ard.2007.086264","article-title":"Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance","volume":"68","author":"Kis","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib0950","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.rhu.0000081470.31167.8b","article-title":"Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis","volume":"9","author":"Perez-Ruiz","year":"2003","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0955","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41584-024-01092-x","article-title":"The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout","volume":"20","author":"Yokose","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0960","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jbspin.2024.105826_bib0965","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0970","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0975","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial","author":"Mayne","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2024.105826_bib0980","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.jbspin.2024.105826_bib0985","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2012.01.092","article-title":"Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials","volume":"157","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0990","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005344-199907000-00010","article-title":"Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia","volume":"34","author":"Elisaf","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105826_bib0995","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0008-6363(01)00382-0","article-title":"Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT)","volume":"52","author":"Malik","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jbspin.2024.105826_bib1000","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(00)00474-3","article-title":"Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia","volume":"154","author":"Giral","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jbspin.2024.105826_bib1005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/dom.15295","article-title":"The effect of empagliflozin and fenofibrate therapies, alone and in combination, on the serum urate concentration in hyperuricaemic type 2 diabetes","volume":"26","author":"Davis","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jbspin.2024.105826_bib1010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2169\/internalmedicine.49.2597","article-title":"Effect of fenofibrate on uric acid metabolism and urate transporter 1","volume":"49","author":"Uetake","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.jbspin.2024.105826_bib1015","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1093\/rheumatology\/keab231","article-title":"Effects of fenofibrate therapy on renal function in primary gout patients","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105826_bib1020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.104.068312","article-title":"Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I","volume":"311","author":"Brunmair","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jbspin.2024.105826_bib1025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0026-0495(86)90152-6","article-title":"Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate","volume":"35","author":"Anton","year":"1986","journal-title":"Metabolism"},{"key":"10.1016\/j.jbspin.2024.105826_bib1030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/GME.0000000000000953","article-title":"Serum uric acid levels and hormone therapy type: a retrospective cohort study of postmenopausal women","volume":"25","author":"Jung","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.jbspin.2024.105826_bib1035","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1210\/jc.2007-2467","article-title":"Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons","volume":"93","author":"Yahyaoui","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2024.105826_bib1040","doi-asserted-by":"crossref","first-page":"e000584","DOI":"10.1136\/rmdopen-2017-000584","article-title":"Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105826_bib1045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/annrheumdis-2023-eular.3251","article-title":"OP0295\/A 12-week, randomized, double-blinded, placebo-controlled. phase 2b study of safety, tolerability and efficacy of AR882 in gout patients","volume":"82","author":"Wei","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib1050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/annrheumdis-2024-eular.3659","article-title":"POS0268\/AR882, a novel and selective URAT1 inhibitor, significantly reduced tophi in patients with chronic gouty arthritis: results of 12-month outcome from a global trial using digital caliper measurements and dual energy computed tomography","volume":"83","author":"Keenan","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib1055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/jpet.115.231647","article-title":"Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone","volume":"357","author":"Ahn","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jbspin.2024.105826_bib1060","first-page":"1976","article-title":"URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers","volume":"58","author":"Lee","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105826_bib1065","doi-asserted-by":"crossref","first-page":"14668","DOI":"10.1021\/acs.jmedchem.4c01480","article-title":"Discovery of a Potent and Orally Bioavailable Xanthine Oxidase\/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout","volume":"67","author":"Yang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.jbspin.2024.105826_bib1070","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.6113","article-title":"Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor","author":"Hu","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105826_bib1075","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211067304","article-title":"Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study","volume":"14","author":"Tang","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib1080","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1093\/rheumatology\/keab198","article-title":"Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study","volume":"60","author":"Lin","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105826_bib1085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2024-eular.4573","article-title":"OP0129\/a 12-week, multicenter, randomized, double-blind, placebo-controlled, phase 2 study of ruzinurad (SHR4640) in combination with febuxostat for primary gout and hyperuricemia with an inadequate response to febuxostat alone","volume":"83","author":"Bao","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib1090","unstructured":"Biosciences A. Atom Bioscience Doses First Patient in Phase 2b\/3 Clinical Trial of a New Treatment for Chronic Gout. 2023, October 9th."},{"key":"10.1016\/j.jbspin.2024.105826_bib1095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/annrheumdis-2020-eular.5107","article-title":"OP0205\/phaes I study of D-0120, a novel URAT1 inhibitor in clinical development for hyperuricemia and gout","volume":"79","author":"Zhang","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105826_bib1100","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","article-title":"Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials","volume":"29","author":"Fitz-Patrick","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105826_bib1105","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1681\/ASN.0000000000000326","article-title":"Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.jbspin.2024.105826_bib1110","unstructured":"Evopoint. Evopoint published Phase II clinical trial data of XNW3009, a new drug against gout. 2022."}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24001374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24001374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T12:40:49Z","timestamp":1741092049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X24001374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1297319X24001374"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105826","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing gout treatment: A comprehensive review of current and emerging uricosurics","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\ufffdt\ufffd Fran\ufffdaise de Rhumatologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105826"}}